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Summary The pharmacokinetics of Zn-phthalocyanine (Zn-Pc) in mice bearing a transplanted MS-2 fibrosar-
coma has been studied using dipalmitoyl-phosphatidylcholine (DPPC) liposomes and low density lipoproteins
(LDL) as drug delivery systems. LDL induce a higher Zn-Pc uptake by the tumour and improve the selectivity
of tumour targeting as compared to DPPC liposomes. Experimental photodynamic therapy (PDT) of the
MS-2 fibrosarcoma has been performed using liposome-delivered Zn-Pc and the efficiency of tumour necrosis
has been measured following four different irradiation protocols. We found that Zn-Pc doses as low as
0.07-0.35 mg kg-' are sufficient for inducing an efficient tumour response that is linearly dependent on the
injected dose. The amount of Zn-Pc in the tumour decreases very slowly as a function of time, hence PDT
gives satisfactory results even if performed at relatively long time intervals after administration.
PDT is a modality for the treatment of solid tumours which
is based on the use of tumour-localising photosensitisers and
irradiation of the tumour with visible light. At the clinical
level, this technique is most frequently applied using
haematoporphyrin or its derivatives (HpD, Photofrin II) as
phototherapeutic agents with red light and satisfactory
results have been generally reported (Dougherty, 1984;
Hayata et al., 1982; Shumaker & Hetzel, 1987). However,
there is now general agreement that these porphyrins are not
ideal photosensitisers owing to the small efficiency of red
light absorption and chemical heterogeneity (Kessel, 1986a).
Other photosensitisers, such as phthalocyanines, are being
studied in vitro and in vivo as possible candidates for replac-
ing HpD in PDT (Spikes, 1986). The phthalocyanines are
characterised by strong light absorption in the 670-690 nm
region (a-105 M-'cm-') and can efficiently photosensitise
both the oxidation of simple substrates (Langlois et al., 1986)
and the killing of cultured cells (Ben-Hur & Rosenthal, 1985;
Chan et al., 1986). Moreover, phthalocyanines are
accumulated and retained by experimental tumours,
especially those of the central nervous system (Rosseau et al.,
1985; Tralau et al., 1987a) causing their destruction upon
illumination with red light (Brasseur et al., 1987; Tralau et
al., 1987b). Most investigations have been performed with the
sulphonated derivatives of the phthalocyanines because of
their high water solubility. The chemical procedure used in
obtaining the sulphonated phthalocyanines generally gives a
mixture of molecules with a different degree of sulphonation,
while the non-sulphonated phthalocyanines can be easily
obtained with a very high purity (Moser & Thomas, 1983).
The latter are very hydrophobic compounds and can be used
in vivo only after their inclusion into lipid matrices. We have
reported a procedure for the incorporation of Zn-Pc into
small unilamellar vesicles of DPPC (Valduga et al., 1987).
The photosensitising efficiency of this phthalocyanine in vitro
has also been documented (Valduga et al., 1988).
We have previously shown that serum lipoproteins are the
exclusive carriers of Zn-Pc 'in vivo' (Reddi et al., 1987). The
transport of photosensitising (Reddi et al., 1987) and cyto-
static (Vitols et al., 1985) agents by LDL has been proposed
in order to improve the selectivity of tumour targeting.
Photofrin II is also delivered to cultured fibroblasts by LDL
via a receptor-mediated endocytotic mechanism; this por-
phyrin is taken up by cells more efficiently when complexed
with LDL than other serum proteins (Candide et al., 1986).
In this paper we report a comparative pharmacokinetic
study of Zn-Pc injected into tumour-bearing mice after
incorporation into DPPC liposomes (Zn-Pc-DPPC) or in
vitro complexation to human LDL (Zn-Pc-LDL). PDT has
been performed after the administration of Zn-Pc-DPPC and
the extent of the photoinduced tumour necrosis has been
measured as a function of different experimental parameters.
Materials and methods
Chemicals
Zn-Pc was a gift from Ciba-Geigy (Basel, Switzerland) and
has been used as received. Previous analysis of the compound
showed a degree of purity of 97% (Valduga et al., 1987).
DL-M-DPPC was a product of Sigma Chemical Co. All other
chemicals and solvents were analytical grade reagents.
Animals and tumour
Female Balb/c mice (18-20g body weight) obtained from
Charles River (Como, Italy) have been used as experimental
model. The mice were grown in cages with free access to
standard dietary chow and tap water. Animal care was made
according to the guidelines established by the Italian commit-
tee for experiments on animals. The MS-2 fibrosarcoma has
been supplied by Istituto Nazionale dei Tumori, Milan. The
tumour was implanted in the right hind leg of the mice by
injection of 0.25 ml of a cell suspension containing at least
106 cells ml-'. All the experiments were started at 8 days
after tumour implantation, when its diameter was
0.7-0.8 cm. When necessary, the mice were anaesthetised by
i.p. injection of ketalar (150mgkg-').
Drugpreparation
Zn-Pc was incorporated into small unilamellar vesicles of
DPPC following the procedure described by Valduga et al.
(1987). For these experiments liposomes were prepared in
0.9% aqueous NaCl and before injection they were dialysed
for 3 h against 250 ml of NaCl with a change of the NaCl
solution after the first hour.
The Zn-Pc was complexed in vitro with human LDL after
isolation of this lipoprotein fraction (1.006<d<1.063) by
density gradient ultracentrifugation (Havel et al., 1955) of
blood samples obtained from normolipidaemic volunteers.
The isolated LDLs were dialysed overnight at 4°C, against
0.01 M phosphate buffer, pH 7.4, with a change of the buffer
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after the first hour. The Zn-Pc was incorporated into LDL
by the slow addition of a I mM stock solution of the drug in
pyridine, which had been 5-fold diluted with absolute
ethanol, to an aqueous solution, pH 7.4, of
LDL(- 7 mg ml-'). The added volume of the Zn-Pc solution
was one-tenth the volume of the lipoprotein solution. During
the addition, the lipoprotein solution was kept at 37°C. In
order to remove the organic solvents, the Zn-Pc-LDL com-
plex was dialysed at room temperature for 3 h against phos-
phate buffer at pH 7.4 with one change of the buffer after the
first hour.
The Zn-Pc concentration in the liposomal vesicles or in the
lipoproteins was measured by absorbence at 673 nm using
a = 2.41 x I05 M-'cm- in pyridine (value determined in our
laboratory).
Pharmacokinetic studies
The Zn-Pc-DPPC or the Zn-Pc-LDL were injected i.v. into
tumour-bearing mice at a dose of 0.12 mg kg-'. At different
times after injection the animals were killed, serum samples
as well as the tumour and several normal tissues were col-
lected for the analysis of their Zn-Pc content. The tissues
were washed with saline solution and frozen until the analysis
was performed. The concentration of Zn-Pc in the serum and
in the tissues was measured spectrophotofluorimetrically fol-
lowing the procedure previously described by Reddi et al.
(1987). The assay method was essentially based on tissue
homogenisation in 2% SDS and measurement of the
fluorescence emission intensity of Zn-Pc in the supernatant
was obtained after centrifugation of the homogenate. This
procedure allows an essentially quantitative extraction of the
drug from tissues (Reddi et al., 1987).
Photodynamic therapy
The experimental PDT with Zn-Pc-DPPC was performed by
irradiation of the tumour area with red light (590-750 nm)
isolated from a 250 W halogen lamp equipped with a set of
optical filters. The emitted light was focused into a bundle of
optical fibres having a total diameter of 0.6 cm. The fibre tip
was placed at 1 cm from the tumour surface during the
phototreatments. Tumour irradiation was performed accord-
ing to different protocols (Table I) in order to examine the
effect of various experimental parameters on the extent of the
photoinduced tumour necrosis.
The estimation of the extent of tumour necrosis was per-
formed at 24 h after PDT. The procedure adopted involved
the fixation of the tumour in 4% formalin, followed by
sectioning of the tumour at 2 mm intervals. The width and
depth of the necrotic area were measured for each tissue
slice. The maximum values of width and depth were recorded
for each tumour and their product was chosen for a quan-
titative evaluation of the tumour response. Each point,
reported in the figures describing the PDT data, represents
the mean ( s.d.) from at least three animals.
Results
Pharmacokinetic studies
Serum samples taken from mice at various times after i.v.
injection of Zn-Pc were analysed by column chromatography
as previously described (Reddi et al., 1987). Both DPPC- and
LDL-administered Zn-Pc were found to be exclusively
associated with the lipoprotein fraction, similar to what we
have observed for i.p.-injected Zn-Pc-DPPC (Reddi et al.,
1987). The elimination of Zn-Pc from the serum follows a
biphasic kinetics. About 70% of the drug is eliminated in
about 12 h while the remaining fraction is eliminated rather
slowly: Zn-Pc levels as low as approx. 40 ng ml-' are present
in the serum at 7 days after the i.v. injection. The kinetics of
Zn-Pc clearance from the serum are independent of the
modality used for administration, i.e. via liposomes or LDL.
In Figures 1 and 2 we show the time-dependence of Zn-Pc
concentration in selected tissues after i.v. administration of
Zn-Pc-DPPC and Zn-Pc-LDL, respectively. The recoveries
were estimated for the tumour, the muscle, i.e. the tissue
where the tumour is implanted, and the liver, i.e. the normal
tissue which usually shows a large uptake of systemically
injected photosensitisers (Dougherty, 1984). Each experi-
mental point represents the average of at least three indepen-
dent determinations performed on specimens obtained from
different animals. In the case of Zn-Pc-DPPC the maximum
concentration ofdrug in the tumour was reached by 3 h after
administration (Figure 1), while for the Zn-Pc-LDL about a
two-fold greater maximum accumulation is observed at about
24 h (Figure 2). On the other hand, rather similar recoveries
of Zn-Pc from the liver and muscle are obtained upon injec-
tion of Zn-Pc-DPPC and Zn-Pc-LDL.
The degree of selectivity of drug localisation in the tumour
is usually expressed by the ratio of its concentration in the
tumour and selected normal tissues. In Table II we report the
ratios tumour/liver and tumour/muscle for Zn-Pc at different
times after injection.
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Figure 1 Time dependence of Zn-Pc concentration in tumour
(0 *), liver (0 O) and muscle (A A) of mice
injected with 0.12mgkg-' Zn-Pc-DPPC.
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Figure 2 Time dependence of Zn-Pc concentration in tumour
(0- ), liver (0 O) and muscle (A A) of mice
injected with 0.12mgkg-' Zn-Pc-LDL.
Table I Protocols used in the PDT of the MS-2 fibrosarcoma
Injected Zn-Pc dose Irradiation dose rate Total light dose A t
Protocol (mgkg-') (mWcm 2) (Jcm-') (h)
1 0.14 50-200 300 24
2 0.14 180 150-450 24
3 0.14 180 300 3-72
4 0.07-0.35 180 300 24
A t is the time interval between the Zn-Pc injection and PDT.
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Table II Ratio between the concentration ofZn-Pc in the tumourand
liver and in the tumour and muscle for Zn-Pc-DPPC and
Zn-Pc-LDL
Tumour/liver Tumour/muscle
Time
(h) Zn-Pc-DPPC Zn-Pc-LDL Zn-Pc-DPPC Zn-Pc-LDL
3 0.45 0.47 2.82 2.89
12 0.70 1.25 3.30 4.37
24 0.94 1.85 3.71 5.71
48 1.01 1.32 2.80 4.95
168 1.04 2.27 3.84 4.20
Experimentalphotodynamic therapy
Generally, the tumours irradiated with red light after the i.v.
injection of Zn-Pc-DPPC showed the appearance of a dark
spot within a few hours, which gradually evolved into eschar
formation and loss of part of the tumour mass. In all the
experiments reported here, the extent of tumour response, as
a function of different parameters, has been evaluated at 24 h
after irradiation, i.e. before the loss of any tumour mass.
In Figure 3 we show the extent of the tumour necrosis as a
function of the irradiation dose rate (Table I, protocol 1).
Clearly, the tumour necrosis increases upon increasing the
dose rate. With our light source, tumour necrosis was
observed also in mice not injected with Zn-Pc but only upon
irradiation with dose rates higher than 230mWcm-2, pos-
sibly owing to the onset of thermal damage. The extent of
the necrotic area depends also on the total light dose as
shown by the data obtained with mice irradiated following
protocol 2 (Figure 4). It appears that, under our conditions,
only light doses above 150 Jcm-2 induce detectable tumour
necrosis. For a fixed dose rate and total light dose (protocol
3), the tumour necrosis is dependent on the time interval
between drug administration and PDT (Figure 5). Significant
tumour necrosis is observed for irradiation performed up to
70 h after the Zn-Pc injection, which is in agreement with the
slow clearance of Zn-Pc from the tumour demonstrated by
our pharmacokinetic studies. PDT was not performed at time
intervals longer than 70 h after Zn-Pc injection, because of
the too large tumour dimensions and the appearance of
spontaneous necrosis. It is also clear from Figure 6 that a
linear relationship exists between the extent of the photo-
induced necrotic area and the injected dose of photosen-
sitiser. Such a behaviour is not surprising owing to the low
Zn-Pc doses used in our experiments. The upper limit of the
photosensitiser dose tested by us was 0.35 mg kg-', since at
this dose the photoinduced necrosis involved the whole
tumour mass.
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Figure 4 Extent of the tumour necrosis as a function of the total
light dose. The irradiation conditions are those of protocol 2.
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Figure 5 Extent of the tumour necrosis as a function of the time
interval between Zn-Pc administration and irradiation. For exper-
imental conditions see protocol 3.
120 -
1i00
E
a)
a) 0 m
C.)
a)
z
80 F
60p
40 F
20
0.1 0.2 0.3
Dose Zn-Pc (mg kg-')
0.4
Figure 6 Extent of the photoinduced tumour necrosis as a func-
tion of the injected Zn-Pc dose. Experimental conditions as in
protocol 4.
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Figure 3 Extent of the photoinduced tumour necrosis as a func-
tion of the light dose rate. The mice have been treated according
to protocol 1.
Our data show that relatively large Zn-Pc concentrations can
be complexed 'in vitro' with isolated LDL; thus, this lipo-
protein class can be used 'in vivo' as a Zn-Pc delivery system.
The occurrence of an active LDL-receptor pathway for the
delivery of Zn-Pc to our tumour model is suggested by the
about two-fold larger concentrations of phthalocyanine
observed in the tumour after injection of the Zn-Pc-LDL as
compared with Zn-Pc-DPPC. However, even with LDL as a
carrier, the selectivity of tumour targeting by Zn-Pc is limited
by the fact that LDL-bound Zn-Pc once injected undergoes a
partial redistribution among other lipoprotein classes, mainly
high density lipoproteins (data not shown). The actual
mechanism of Zn-Pc delivery from LDL (and/or other car-
riers) to the tumour tissue is certainly complex and probably
involves the time-dependent redistribution of the dye among
different tissue compartments. A similar behaviour has been
observed for sulphonated porphine derivatives and HpD
components (Kessel et al., 1987; Kessel, 1986b). This might
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explain the lower efficiency of PDT at 3 h as compared to
24 h after Zn-Pc injection (Figure 5) in spite of the almost
identical overall concentration of the photosensitiser in the
tumour (Figure 1).
In any case, it is likely that Zn-Pc, once released inside the
tumour cell, becomes associated with apolar compartments
owing to its hydrophobic character. Ultrastructural studies
on mouse tumour tissues, which had been irradiated in the
presence of Zn-Pc, showed that the cytoplasmic and
mitochondrial membranes were heavily damaged (Milanesi et
al., 1987). This endocellular distribution of Zn-Pc can explain
the slow release of this drug from the tumour. We have
previously demonstrated that Zn-Pc is eliminated from the
body by the bile-gut pathway (Reddi et al., 1987). This
requires the removal of Zn-Pc from the tumour and its
transport to the liver by serum proteins; thus the slow
clearance of Zn-Pc may depend on the low accessibility of
the drug binding sites to the protein carriers. The poor
lymphatic drainage typical of tumour tissues has also been
invoked to explain the slow release of photosensitising drugs
(Bugelski et al., 1981). The high degree of selectivity of
tumour targeting by our procedure for Zn-Pc administration
and transport is underlined by the fact that at 24h after
injection similar or larger amounts of Zn-Pc are found in the
tumour as compared to the liver (see Figures 1 and 2).
Moreover, the constantly low levels of Zn-Pc in the muscle
should indicate that there is only a minimal risk of damage
to normal tissues adjacent to the tumour during PDT.
The slow clearance of Zn-Pc by the tumour also suggests
the possibility of multiple phototreatments following a single
Zn-Pc injection. Our PDT data show that irradiations per-
formed at 70 h after Zn-Pc administration induce an efficient
tumour necrosis and, on the basis of our pharmacokinetic
data (Figure 1), it is likely that similar tumour response are
obtained by PDT treatments performed at 7 days after Zn-Pc
injection. These considerations are reinforced by the finding
(Figure 6) that Zn-Pc doses as low as 0.07 mg kg-' are
sufficient for inducing an important tumour necrosis. The
linearity of the plot of the tumour responses against Zn-Pc
dose (Figure 6) is due to the low amounts of photosensitising
agent used in our experiments. On the other hand, Tralau et
al. (1987b) found that the extent of tumour response to PDT
tends toward a plateau value upon injection of sulphonated
Al-Pc doses above 1 mg kg-'. It is likely that in the presence
of large dye concentrations in the tumour the incident light is
efficiently absorbed only by the superficial layers of the tis-
sue, thus reducing the optical penetration depth.
The extent of the tumour necrosis for a given Zn-Pc dose
depends on the total light dose (see Figure 4), as already
observed by other authors for porphyrins (Fingar et al.,
1987) and phthalocyanines (Tralau et al., 1987b) and
expected on the basis of theoretical considerations (Doiron et
al., 1984). The extent of tumour necrosis depends also on the
irradiation dose rate (see Figure 3). In particular, we
observed about a 6-fold increase of the necrotic area from 50
to 200mWcm2. For unsensitised animals no tumour nec-
rosis could be detected up to 230 mW cm2. Moreover, upon
irradiation of Zn-Pc-injected mice with dose rates around
180 mW cm-2, the temperature increase of the tumour tissue,
as measured with an infra red sensitive telecamera (Vietri et
al., 1988), was below 3-4°C, which is lower than that usually
considered to originate hyperthermal effects (Evensen &
Moan, 1988). However, a synergism between this modest
temperature increase and photodynamic effects cannot be
ruled out. The occurrence of such a synergism might explain
the upward deviation from linearity observed above about
130 mW cm-2 in the plot describing the influence of dose rate
on the extent of the necrotic area (Figure 3).
Our pharmacokinetic studies show that a fraction of the
Zn-Pc is cleared from the serum at a slow rate; this circum-
stance may be responsible for some cutaneous photosen-
sitivity (Zalar et al., 1977). However, our pharmacokinetic
studies showed that only negligible amounts of Zn-Pc
(around 0.1 tgg-' tissue) are accumulated in the skin
between 3 h and 1 week after administration. This should
minimise the risk of skin photosensitisation. The latter
should be also minimised by the spectral properties typical of
phthalocyanines which absorb ambient light much less
efficiently than porphyrins.
In conclusion Zn-Pc appears to be a very promising
photodynamic agent for the therapy of tumour due to its
selective localisation in and slow clearance from the tumour,
and the efficient photosensitisation of tumour necrosis even
upon injection at very low doses.
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